Silexion Therapeutics Appoints New CMO, Board Member
Ticker: SLXNW · Form: 8-K · Filed: Dec 10, 2024 · CIK: 2022416
Sentiment: neutral
Topics: leadership-change, board-appointment, warrants
Related Tickers: SLXN
TL;DR
Silexion Therapeutics beefs up leadership with a new CMO and board member.
AI Summary
On December 10, 2024, Silexion Therapeutics Corp. announced the appointment of Dr. Yaron Paz as Chief Medical Officer and Dr. Shimon Eckhouse as a new board member. The company also reported on the exercise of warrants, resulting in the issuance of ordinary shares.
Why It Matters
The appointment of a new Chief Medical Officer and board member suggests a strategic focus on clinical development and governance, potentially impacting the company's future research and strategic direction.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Dr. Yaron Paz (person) — Appointed Chief Medical Officer
- Dr. Shimon Eckhouse (person) — Appointed Board Member
- December 10, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Yaron Paz has been appointed as the new Chief Medical Officer.
Who has joined the board of directors?
Dr. Shimon Eckhouse has joined the board of directors.
What is the company's primary business?
The company is in the business of Biological Products (No Diagnostic Substances).
When was the company's name changed from its former name?
The company's name was changed from Biomotion Sciences on May 6, 2024.
What is the exercise price for the warrants mentioned?
The warrants are exercisable for ordinary shares at an exercise price of $1.50 per share.
Filing Stats: 913 words · 4 min read · ~3 pages · Grade level 13.6 · Accepted 2024-12-10 08:48:13
Key Financial Figures
- $0.0001 — registered Ordinary Shares, par value $0.0001 per share SLXN The Nasdaq Stock Mar
- $11.50 — Ordinary Shares at an exercise price of $11.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2432451.htm (8-K) — 53KB
- exhibit_99-1.htm (EX-99.1) — 15KB
- image00003.jpg (GRAPHIC) — 3KB
- 0001178913-24-003954.txt ( ) — 258KB
- slxn-20241210.xsd (EX-101.SCH) — 5KB
- slxn-20241210_def.xml (EX-101.DEF) — 18KB
- slxn-20241210_lab.xml (EX-101.LAB) — 27KB
- slxn-20241210_pre.xml (EX-101.PRE) — 20KB
- zk2432451_htm.xml (XML) — 6KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of New Independent Director On December 10, 2024, the Board of Directors (the " Board ") of Silexion Therapeutics Corp (the " Company ") appointed Professor Amnon Peled to the Board as an independent director. Professor Peled will serve for a term that lasts until the Company's next annual general meeting, and will fill the Board seat vacated by Ilan Shiloah, who had resigned in September 2024. Professor Peled will serve on each of the audit, compensation, and corporate governance and nominating committees of the Board, and has been affirmed by the Board to (i) be an "independent director" as defined by Nasdaq Listing Rule 5605(b)(1) and (ii) meet the further requirements for audit committee and compensation committee service contained in Nasdaq Listing Rules 5605(c)(2)(A) and 5605(d)(2)(A), respectively, including under Rules 10A-3 and 10C-1 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "). Professor Peled's appointment to the audit committee is expected to remedy the Company's Nasdaq listing deficiency related to the composition of the audit committee, by bringing to three the number of qualified directors serving on that committee. As previously disclosed, on November 19, 2024, the Company had been notified by The Nasdaq Stock Market LLC that, as a result of the resignation of Ilan Shiloah from the audit committee, the Company was not in compliance with Nasdaq's audit committee composition requirements as set forth in Nasdaq Listing Rule 5605(c)(2)(A), which required the Company to have three qualified members of the audit committee. Biographical information with respect to Professor Peled is set forth immediately below: Amnon Peled , PhD, has served as an associate professor at Hadassah Medical Center, Jerusalem since August 2000. Professor Peled also served as Di
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated December 10, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: December 10, 2024 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer